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Aim. To determine the cardiovascular risk and the concordance between the different scores in people with rheumatoid arthritis
(RA) and psoriatic arthritis (PsA). Methods. Observational descriptive study of prevalence. Performed in the Rheumatology
Service and the Clinical Epidemiology and Biostatistics Unit of the University Hospital Complex of A Coruña (Spain). Patients
diagnosed with RA or PsA, older than 18 years of age were included. Measurements: sociodemographic, anthropometric variables
of the disease, comorbidity, cardiovascular risk, and therapeutic management. Results. 151 subjects (75 RA and 76 PsA) were
studied. ,e average age was 57.9± 12.2 years, 61.6% being women. ,e average of the Charlson index was 2.8± 1.5. 43% were
overweight. 46.5% were classified as cardiovascular risk, and the average percentage was 33.3% by Framingham. ,e best
agreement has been between Framingham and Dorica (k� 0.709; p< 0.001), classifying more than 80% of the cases in the same
risk categories. Conclusions. ,e most prevalent risk factors were overweight and obesity, followed by smoking and hypertension.
,e prevalence of patients with moderate/high cardiovascular risk varies according to the score used, the levels of concordance
being the scores of Framingham and Dorica.
1. Introduction
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are
two of the most prevalent rheumatic diseases which have an
impact on the health system [1]. Among the repercussions of
these diseases, their relationship with an increase in car-
diovascular disease (CVD) [2, 3], morbidity, and mortality
[1] stands out, owing to the role played by inflammation in
both pathologies [4]. ,us, it has been observed that the
CVD condition is the main cause of death, both in people
with RA and in people with PsA [5, 6]. In the case of RA, life
expectancy has been reduced from 3 to 10 years compared
with the general population [7]. ,e cardiovascular risk
(CVR) factors described in the literature are cholesterol,
diabetes, hypertension, genetic inheritance, stress, tobacco,
physical inactivity, obesity, and heart rate [8]. ,e CVD
establishes the probability of suffering in a given period of
time, generally 5 or 10 years, a cardiovascular episode [9].
,e scientific literature reveals that the risk factors described
and attributed to RA are hypertension, dyslipidemia [3],
physical inactivity, obesity, and diabetes [10, 11], defined as
highly prevalent in this population [12]. ,ese factors can be
fed back by the disease itself, as in the case of pain, which
contributes to physical inactivity and obesity. Furthermore,
it has been seen that the increase in CVR in people with RA
has an effect similar in magnitude to that of diabetes [13]. A
higher prevalence of heart failure [14, 15] and of acute
myocardial infarction (41–68%) has also been found with
respect to the general population [16, 17].
People with PsA [18] have more CVR factors than people
with RA [19], constituting one of the most relevant causes of
death [6].
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In this way, the magnitude of the problem induces the
interest of studying the recognized increase in CVR in these
diseases [5], if it is also taken into account that it constitutes
the main cause of death in these populations [20].
,erefore, the aim of the present research was to de-
termine the CVR and the concordance between the different
scores in people with RA and PsA.
2. Methods
An observational descriptive study of prevalence was carried
out in the Rheumatology Service and in the Clinical Epi-
demiology and Biostatistics Unit of the University Hospital
Complex of A Coruña (CHUAC) (A Coruña, Spain). Pa-
tients diagnosed with RA or PsA were included in the study
who went consecutively to the Rheumatology Service during
the study period (December 2016 to July 2017) and who gave
their written informed consent to participate in the study.
,e study was approved by the Clinical Research Ethics
Committee of Galicia (CEIC 2016/544). ,e following
variables were studied for each person included in the re-
search: sociodemographic variables (age, sex, family history,
smoking habit, level of studies, work situation, and type of
activity); anthropometric variables (body mass index
(BMI)); abdominal circumference (cm), hip (cm), and neck
(cm); waist circumference index (WCI) (cm); waist height
index (WHI) (cm)); disease variables (type of time evolution
of the disease); comorbidity variables (Charlson comorbidity
index [21], systolic blood pressure (SBP), diastolic blood
pressure (DBP), ankle-brachial index (ABI), total cholesterol
level, HDL-cholesterol, left ventricular hypertrophy, and
diabetes mellitus); cardiovascular risk (Framingham–
Wilson, Score, Dorica, and Regicor) [22]; and therapeutic
management variables (medication at the time of the in-
terview). An electrocardiogram was performed on all par-
ticipants in the study. ,e data were obtained from the
examination and the clinical history and through the ana-
lytical parameters.
To perform the ABI, the patient was placed in the supine
position. A cuff was used for the arm and another for the
ankle of at least 40% of the circumference of the limb. ,e
sleeve should be clean and dry. Doppler tube from 8 to
10MHz was used. ,e blood pressure was taken simulta-
neously in the 2 arms with the validated automatic device
Microlife WATCH BP OFFICCE ABI®, which determinesdifferences between the 2 arms, making 3 measurements
separated by one minute each, and making, the same device,
an average of the 3 measurements in each arm. ,e device is
validated for patients with atrial fibrillation and to perform
the ABI automatically. It was measured in the posterior tibial
artery (in the lower limbs) and the cuff was placed above the
malleoli. ABIs with values <0.99 and ≥1.30 were considered
pathological. ,e process was always performed by the same
nurse in all patients.
To perform the electrocardiogram, the patient was
placed on the stretcher, with the thorax, ankles, and wrists
exposed, with arms and legs separated from the body. ,e
corresponding electrodes were placed. ,e speed of the
paper was adjusted to 25mm/second and the tension to
10mm/mv, and the way to do it in automatic mode was
selected. ,e PageWriter TC20/TC30 electrocardiograph
was used.
To avoid the variability of these measuring instruments,
the recommendations of the manufacturers were followed.
,e devices were checked every 6months. ,e measure-
ments were always carried out by the same nurse, using the
same procedure.
A descriptive study of the variables was carried out. ,e
comparison of means between two groups was carried out
using the Student’s t-test or the Mann–Whitney test as
appropriate after verification of normality with the
Kolmogorov–Smirnov test. ,e association of qualitative
variables was determined with the chi-square or Fisher’s test
as appropriate. ,e p value <0.05 has been considered as
statistically significant. ,e concordance between the dif-
ferent scores was analyzed through the kappa concordance
index.
3. Results
,e general and comorbidity characteristics are shown in
Table 1. ,e mean age at the time of the interview was
57.9± 12.2 years, 61.6% being women. ,e mean evolution
of the disease was 9.2± 7.6 years, and the Charlson
comorbidity index was 2.8± 1.5. In terms of BMI, a high
percentage of overweight (43%) and obesity (28.5%) was
observed. 19.9% declared to be a smoker and 31.8% ex-
smoker. 71.5% did not present a family history of the study
pathologies (RA and PsA).
,e people diagnosed with RA showed greater age at
diagnosis (51.1± 12.2 vs 46.4± 13, p � 0.024), predominance
of the female sex (77.3% vs 46.1%, p< 0.001), and of basic
studies (64% vs 45.3%, p � 0.022). Both groups showed
similar BMI and comorbidity index. In contrast, a higher
Charlson index adjusted for age was observed in patients
with RA (3.1± 1.5 vs 2.5± 1.4, p � 0.020).
Table 2 shows the CVR of the sample studied and its
factors. ,e most prevalent pathology in our sample was
hypertension (39.6%), followed by diabetes (10.3%), 8.1%
being without target organ damage. Ventricular hypertrophy
was present in 4.6% of cases. As for various anthropometric
measurements, the mean of theWCI was 0.9± 0.1 and that of
the WHI of 0.6± 0.1. None of these measurements showed
statistically significant differences between the study pa-
thologies. ,e patients presented total cholesterol of
205.2± 37.8mg/dl, with mean values of LDL
122.1± 31.9mg/dl and HDL 57.2± 15.4mg/dl, showing no
differences between the RA and PsA.
,e mean of the ABI was 1.2± 0.1 and the heart rate in
the sample studied was 71.3± 13.4, without finding signif-
icant differences between the two pathologies studied. Ta-
ble 3 shows the CVR classified according to the different
scores as well as the concordance between them. ,us, it has
been classified as moderate/high by 46.5% according to
Score, by 33.3% according to Framingham, by 24.1%
according to Dorica, and by 4.3% according to Regicor. A
good concordance between Framingham and Dorica is
observed (k� 0.709; p< 0.001), classifying more than 80% of
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the cases in the same risk categories. Also, the agreement was
good between Framingham and Score (k� 0.464; p< 0.001),
classifying more than 70% of the cases in the same risk
categories. ,e characteristics and CVR factors were com-
pared between the general population and rheumatic dis-
eases in Table 4.,e BMI observed in the general population
is higher than that observed in patients with rheumatic
disease, there being significant differences in the case of RA.
(29.2± 4.7 vs. 27.7± 4.8, p � 0.006). A lower comorbidity
was observed in the general population, being significantly
lower in relation to the present one in RA (2.2± 1.8 vs
3.1± 1.5, p< 0.001). ,e general population showed sig-
nificantly higher LDL cholesterol values than those observed
in patients with rheumatic disease. ,e most prevalent
pathology in the general population was hypertension
(36.5%), showing a similar percentage to that observed in RA
(34.7%) and PsA (43.4%).
4. Discussion
In our study, the mean age of the patients at the time of
diagnosis of arthritis was 48.7 years, with a predominance of
females: data similar to those observed in the CARMA [23]
project and a more recent study by Castañeda [24]. In the
comparison between patients with RA and PsA, results were
found in agreement with those obtained in the CARMA
multicenter project, with a greater age at diagnosis in pa-
tients with RA, mostly women. In the literature, we find
articles [20, 25–28] that deal with the topic of study, re-
vealing the influence of cardiovascular diseases in rheumatic
diseases, and thus exposing their importance. Research on
CVR factors in PsA is scarcer than that in RA or with
psoriasis [29].
,e literature concludes the increase in CVR in these
diseases, as well as in morbidity and mortality, constituting
the systemic inflammation itself as an independent CVR
factor [30–32], not forgetting the contribution of tradi-
tional risk factors (which can be modified by medication)
[2, 26].
In general, the traditional factors of hypertension, di-
abetes, and obesity have a great association with RA and
PsA (and this is also in case with hyperlipidemia) [32–34].
In relation to the BMI, we found high data of overweight
(44.0%) and obesity (26.7%) in our article. Accordingly,
Kitas and Gabriel [5] affirm that the relationship between
BMI and mortality in people with RA is remarkable, due to
Table 1: General characteristics and comorbidity of the global sample and according to the type of arthritis.
Global, n � 151 Rheumatoid arthritis, n � 75 (49.7%) Psoriatic arthritis, n � 76 (50.3%)
Mean± SD Mean± SD Mean± SD p
Age dx (years) 48.7± 12.8 51.1± 12.2 46.4± 13 0.024
Age interview (years) 57.9± 12.2 60± 12.4 55.8± 11.8 0.037
BMI (kg/m2) 28± 5.1 27.7± 4.8 28.3± 5.3 0.445
Charlson index 1.4± 0.8 1.4± 0.8 1.3± 0.7 0.320
Adjusted Charlson index 2.8± 1.5 3.1± 1.5 2.5± 1.4 0.020
n (%) n (%) n (%) p
Sex <0.001
Male 58 (38.4) 17 (22.7) 41 (53.9)
Female 93 (61.6) 58 (77.3) 35 (46.1)
Family history <0.001
No 108 (71.5) 68 (90.7) 40 (52.6)
Yes 43 (28.5) 7 (9.3) 36 (47.4)
BMI (kg/m2) 0.910
Normal (BMI< 25) 41 (27.2) 20 (27.4) 21 (27.6)
Overweight (25≥BMI< 30) 65 (43) 33 (45.2) 32 (42.1)
Obesity (BMI≥ 30) 43 (28.5) 20 (27.4) 23 (30.3)
Smoking habit 0.066
Nonsmoker 73 (48.3) 36 (48) 37 (48.7)
Ex-smoker 48 (31.8) 29 (38.7) 19 (25)
Smoker 30 (19.9) 10 (13.3) 20 (26.3)
Studies 0.022
No/primary 82 (54.3) 48 (64) 34 (45.3)
Superior 68 (45) 27 (36) 41 (54.7)
Employment situation 0.148
Inactive 94 (62.3) 51 (68) 43 (56.6)
Active 57 (37.7) 24 (32) 33 (43.4)
Type of activity 0.509
Seated 18 (11.9) 7 (14.9) 11 (21.2)
Standing/movement 51 (33.8) 27 (57.4) 24 (46.2)
Mixed 30 (19.9) 13 (27.7) 17 (32.7)
Medication
Methotrexate 77 (56.6) 40 (57.1) 37 (56.1) 0.899
Age dx: age at diagnosis; BMI: body mass index.
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the greater accumulation of body fat (known as rheumatoid
cachexia) [35], unlike other investigations [33, 36] that
claim to see that some patients have a low BMI associated
with higher CVD mortality [30]. Likewise, no data have
been found in other studies on the results of the different
anthropometric data shown in this article (such as the
waist–hip index), which is highly recommended [36], but it
is noteworthy that abdominal fat is associated with insulin
resistance, cardiometabolic risk, and the inflammatory load
[5]. For its part, despite the scarcity of studies on body
composition in PsA, it is reported that excess adiposity
increases the CV [35] risk, being closely related to obesity
[28], being associated with a greater metabolic risk than
RA, and constituting obese BMI as a risk factor for psoriasis
[37].
In our study, we found almost 20% of smokers; similar
results in other researches (15.6%) [38]were observed. ,is
smoking habit is associated with an increased risk of de-
veloping RA and increased activity of the disease [30]. In
relation to hypertension, 35.6% RA and 43.4% PsA suffered
it in the study sample. Lower percentages were objectified in
other studies in RA (7.3%) [13]. Regarding PsA, Panoulas
Table 2: Cardiovascular risk factors and scores.
Global, n � 151 Rheumatoid arthritis, n � 75 (49.7%) Psoriatic arthritis, n � 766 (50.3%)
Mean± SD Mean± SD Mean± SD p
Perimeter (cm)
Abdominal 97.8± 13.8 97.6± 13.0 98.1± 14.7 0.823
Hip 102.4± 10.4 103.1± 10.2 101.8± 10.6 0.454
Neck 37.8± 4.5 37.8± 4.2 37.9± 4.7 0.861
WCI (cm) 0.9± 0.1 0.9± 0.1 0.9± 0.1 0.768
WHI (cm) 0.6± 0.1 0.6± 0.1 0.6± 0.1 0.423
Total cholesterol 205.2± 37.8 208.6± 40.7 201.9± 34.7 0.133
HDL 57.2± 15.4 59.0± 16.7 55.3± 13.8 0.158
LDL 122.1± 31.9 121.8± 33.7 122.5± 30.9 0.904
Ankle-brachial index 1.2± 0.1 1.2± 0.1 1.2± 0.1 0.929
Heart rate 71.3± 13.4 70.7± 14.5 71.8± 12.3 0.684
Cardiovascular risk scores
Framingham 9.8± 8.6 9.6± 8.1 9.9± 9.1 0.807
Regicor 3.9± 3.1 3.7± 2.7 4.0± 3.6 0.640
Dorica 6.4± 5.9 5.9± 5.5 6.8± 6.3 0.386
Score 1.9± 2.2 2.1± 2.2 1.7± 2.1 0.281
n (%) n (%) n (%) p
LVH 0.276
No 144 (95.4) 70 (93.3) 74 (97.4)
Yes 7 (4.6) 5 (6.7) 2 (2.6)
Arterial hypertension 0.330
No 90 (60.4) 47 (64.4) 43 (56.6)
Yes 59 (39.6) 26 (35.6) 33 (43.4)
Charlson index
PAD 1 (0.7) 1 (100.0) 0 (0.0) 0.515
Cerebrovascular disease 1 (0.7) 1 (100.0) 0 (0.0) 0.515
Heart failure 2 (1.5) 1 (50.0) 1 (50.0) 0.737
AMI 3 (2.2) 2 (66.7) 1 (33.3) 0.522
Diabetes 14 (10.3) 7 (50.0) 7 (50.0) 0.979
Without organ damage 11 (8.1) 5 (45.5) 6 (54.5) 0.459
With organ injuries 3 (2.2) 2 (66.7) 1 (33.3) 0.522
WCI: waist circumference index; WHI: waist height index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LVH: left ventricular hypertrophy;
PAD: peripheral arterial disease; AMI: acute myocardial infarction.
Table 3: Classification of cardiovascular risk according to the different scores and concordance.
Framingham Dorica Regicor Score
n (%) n (%) n (%) n (%)
Low risk 94 (66.7) 107 (75.9) 135 (95.7) 77 (53.5)
Moderate-high risk 47 (33.3) 34 (24.1) 6 (4.3) 67 (46.5)
Concordance study Dorica Regicor Score
K (p) K (p) K (p)
Framingham 0.709 (<0.001) 0.163 (<0.001) 0.464 (<0.001)
Dorica 0.245 (<0.001) 0.296 (<0.001)
Regicor 0.066 (0.067)
K: kappa concordance index; p: p value.
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et al. [39] state that it is superior in patients with RA, ranging
from 4 to 73%, being the cause of the sample sizes, the
definition of hypertension, or the study population.
,erefore, it is not clear that there is a higher prevalence of
this pathology than in the RA or general population. More
similar data with other investigations correspond to those of
DM and RA (prevalence of 10%) [38], with a higher
prevalence of this condition in PsA (23%) [31].
On the other hand, the literature shows inconsistent
findings about lipid levels as the disease evolves, with a clear
alteration of the lipid profile [35]. In our study, with an
average time of evolution of the disease of 9.2 years, we
obtain an average of total cholesterol of 208.6 and LDL 121.8.
,is LDL value is lower than that found in the general
population, as in other investigations [40], which can be
explained by the evolution of the disease [41] and ques-
tioning its clinical relevance in RA [40].
Reviewing the literature, Jurcut et al. [42] found an
increased risk of myocardial infarction in people with RA.
Regarding PsA, it is related to higher prevalences of heart
diseases (heart failure or cerebrovascular disease) [29]. In
line with the above, we have not found data to contrast our
results on left ventricular hypertrophy in the study pop-
ulations, as well as to relate the Charlson comorbidity score
with the pathologies under study. It could be mentioned in
this discussion that antirheumatic drugs, especially meth-
otrexate and/or biologics, appear to reduce CVR by effec-
tively decreasing systemic inflammation [41].
In relation to the CVD scores, Arts et al. [43], after
reviewing the literature, state that the risk score of Fra-
mingham, Reynolds, and Score classify 60% of patients with
RA as lower risk, agreeing with other investigations in which
they underestimate CVR in RA [43]. Liao and Solomon [11]
describe the need to develop scores that include in-
flammatory markers in addition to traditional cardiovas-
cular risk factors so as not to underestimate CVR in these
conditions [44, 45]. In our study, the scores show higher
prevalences in a low CVR, which may be due to the time of
evolution of the disease or the treatment received [43], since
the events are more common within the first 7 years of the
disease.
5. Conclusions
Cardiovascular risk factors have a great impact on people
with RA and PsA. ,e most prevalent were overweight and
obesity, followed by smoking and hypertension. ,e prev-
alence of moderate/high cardiovascular risk varies according
to the score used, the Framingham and Dorica scores being
the most concordant. ,e control of the disease in an in-
tegral way constitutes a fundamental field in the reduction of
CVD risk in both diseases, fundamental for the quality of life
of people with RA and PsA.
Data Availability
,e data used to support the findings of this study are re-
stricted by the Clinical Research Ethics Committee of Galicia
in order to protect patient privacy. Data are available from
Cristina González-Mart́ın, Research Group in Clinical Ep-
idemiology, Department of Health Sciences, Faculty of
Nursing and Podiatry, University of A Coruña (UDC),
Ferrol Campus, Ferrol, Spain, for researchers who meet the
criteria for access to confidential data.
Table 4: Characteristics of the general population and rheumatic disease cases (RA and PsA).
General population
n � 1844
Rheumatoid arthritis, n � 75
(49.7%)
Psoriatic arthritis, n � 76
(50.3%)
Mean± SD Mean± SD p1 Mean± SD p2
BMI (kg/m2) 29.2± 4.7 27.7± 4.8 0.006 28.3± 5.3 0.103
Adjusted Charlson index 2.2± 1.8 3.1± 1.5 <0.001 2.5± 1.4 0.630
Abdominal perimeter
(cm) 95.5± 12.7 97.6± 13.0 0.160 98.1± 14.7 0.082
LDL 132.0± 31.4 121.8± 33.7 0.006 122.5± 30.9 0.009
Ankle-brachial index 1.2± 3.5 1.2± 0.1 0.999 1.2± 0.1 0.999
n (%) n (%) p1 n (%) p2
Charlson index
PAD 74(4.1) 1(1.3) 0.384 0(0.0) 0.139
Cerebrovascular disease 74(4.1) 1(1.3) 0.384 0(0.0) 0.139
Heart failure 31(1.7) 1(1.3) 0.818 1(1.3) 0.831
AMI 87(4.8) 2(2.7) 0.583 1(1.3) 0.267
Diabetes 244 (13.4) 7 (9.3) 0.326 7 (9.2) 0.308
Without organ
damage 217(11.9) 5(6.7) 0.242 6(7.9) 0.395
With organ injuries 27(1.5) 2(2.7) 0.723 1(1.3) 0.702
Arterial hypertension 663(36.5) 26(34.7) 0.916 33(43.4) 0.228
Smoking habit
Nonsmoker 1008(55.0) 36(48) 0.308 37(48.7) 0.363
Ex-smoker 505(27.6) 29(38.7) 0.044 19(25) 0.744
Smoker 320(17.5) 10(13.3) 0.454 20(26.3) 0.064
BMI: body mass index; LDL: low-density lipoprotein; PAD: peripheral arterial disease; AMI: acute myocardial infarction; 1p value for contrasts general
population vs RA; 2p value for contrasts general population vs PsA.
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